The Antisense & RNAi Therapeutics by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Antisense & RNAi Therapeutics Market:
According to The Business Research Company’s Antisense & RNAi Therapeutics, The antisense & rnai therapeutics market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.77 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to rise in funding, advancement in technologies, and rise in healthcare expenditure, rapid growth in elderly population and economic growth in emerging markets.
The antisense & rnai therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increase in healthcare access, rising prevalence of caner and increasing demand for antisense and rnai therapeutics due to covid-19. Major trends in the forecast period include focus efforts towards the research and development of rna therapeutics for orphan diseases, use of nanoparticles, develop new and improved antisense and rnai therapeutics, and collaborate with other companies for product innovation and to drive revenues.
The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases affecting millions of people globally. In the USA, 6.2 million people may have Alzheimer’s disease in the USA . As per January 2023 data approximately 500,000 people in the USA are diagnosed with Parkinson’s disease. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
The antisense & rnai therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives, such as collaborations and partnerships to sustain in the increasingly competitive market. Strategic collaboration is a business strategy that involves two or more companies working together to achieve a common goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company offering services for the discovery of peptides has partnered with SanegeneBio Inc. a UK-based company involved in the developing novel RNAi-based medicines for the identification of tissue-specific delivery of RNA therapeutics for efficient gene knockdown, aiming to develop a portfolio of advanced RNAi therapeutics. The collaboration encompasses hit identification and cell-based internalization studies, with Sanegene having the option to further develop the hits derived from the screening activities, leveraging Orbit's proprietary technology for rapid peptide lead discovery. Orbit Discovery's unique peptide display engine enables the screening of large peptide libraries, offering faster discovery times for relevant peptide leads based on affinity and functional screens.
The antisense & rnai therapeutics market report table of contents includes:
1. Executive Summary
2.Antisense & RNAi Therapeutics Market Characteristics
3.Antisense & RNAi Therapeutics Market Trends And Strategies
4. Antisense & RNAi Therapeutics Market analysis
5.Antisense & RNAi Therapeutics Market Size And Growth
6. Antisense & RNAi TherapeuticsSegmentation
7.Antisense & RNAi Therapeutics Regional And Country Analysis
.
.
.
27.Antisense & RNAi Therapeutics Competitive Landscape And Company Profiles
28.Antisense & RNAi Therapeutics Key Mergers And Acquisitions
29.Antisense & RNAi Therapeutics Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Biogen Inc.
- Ionis Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Moderna Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The new report by Expert Market Research titled, ‘Global Antisense and RNAi Therapeutics Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global antisense and RNAi therapeutics market, assessing the market based on its segments like end-product forms, equipment types, and applications.
The sample report shall be delivered to you within 24 hours.Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/antisense-and-rnai-therapeutics-market/requestsampleThe key highlights of the report include:Market Overview (2016-2026)Forecast CAGR (2021-2026): 8.5%Explore the full report with the table of contents@ https://www.expertmarketresearch.com/reports/antisense-and-rnai-therapeutics-marketIndustry Definition and Major SegmentsSpecific and highly effective gene silencing is possible due to antisense and RNAi therapeutics.
Oncology, cardiovascular disease, respiratory disorders, renal disease, neurodegenerative disorders, genetic disorders, infectious diseases, and other conditions are all treated with it.The Antisense and RNAi therapeutics industry can be divided based on:TechnologyRNA InterferenceSiRNAMiRNAAntisense RNARoute of AdministrationPulmonary DeliveryIntravenous InjectionsIntra-dermal InjectionsIntraperitoneal InjectionsTopical DeliveryMarket TrendThe global antisense and RNAi therapeutics industry is propelled by a deep understanding of gene function for disease management via the use of malfunctioning genes and the control of their gene expression.
Various collaborations between pharmaceutical companies and contract research organisations working to improve drug delivery are also driving the market.The global antisense and RNAi therapeutics market is being driven by the rising prevalence of infectious diseases and neurodegenerative disorders.
Nanocarriers have been shown to improve bioavailability, transporting limits of siRNA payload, and providing high cooperation with target cells.However, stringent regulations, a lengthy product approval process, high development costs, and a relatively small number of patients are just a few of the factors that contribute to the high cost of RNA interference drugs, which is expected to slow the market growth of antisense and RNAi therapeutics in the coming years.Key Market PlayersThe major players within the market are OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceuticals, Benitec Biopharma Ltd, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Antisense Therapeutics Ltd. and others.
The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of those market players.Read More Reports:-Global Sodium Monochloro Acetate Market: https://www.expertmarketresearch.com/reports/sodium-monochloro-acetate-marketGlobal Epigenetics Market: https://www.expertmarketresearch.com/reports/epigenetics-marketGlobal Digital Therapeutics Market: https://www.expertmarketresearch.com/reports/digital-therapeutics-marketGlobal Coco Coir Market: https://www.expertmarketresearch.com/reports/coco-coir-marketGlobal Metal Finishing Market: https://www.expertmarketresearch.com/reports/metal-finishing-marketGlobal Probiotic Supplements Market: https://www.expertmarketresearch.com/reports/probiotic-supplements-marketGlobal Styrene Market: https://www.expertmarketresearch.com/reports/styrene-marketGlobal Brain Computer Interface Market: https://www.expertmarketresearch.com/reports/brain-computer-interface-marketGlobal Wireless Microphone Market: https://www.expertmarketresearch.com/reports/wireless-microphone-marketGlobal Sodium Chlorite Market: https://www.expertmarketresearch.com/reports/sodium-chlorite-marketNote 2: As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours.
San Francisco, CA - Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025.
RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts.
Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell.
The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.
Request a PDF Sample @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come.
However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years.
Antisense & RNAi Therapeutics Global Market Report 2021 by The Business Research Company is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact – both negative and positive – of COVID-19 on the antisense & RNAi therapeutics industry gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
This includes revised market numbers according to the effects of the coronavirus and the expected antisense & RNAi therapeutics market growth numbers 2021-2030.
View Complete Report:https://www.thebusinessresearchcompany.com/report/antisense-and-RNAi-therapeutics-market-global-report-2020-30-covid-19-growth-and-change The Antisense & RNAi Therapeutics Global Market Report 2020-30 by The Business Research Company provides an in-depth analysis of the global antisense & RNAi therapeutics market and covers both the historic period, 2015 to 2020, and the forecast period, 2020 to 2030.
The report evaluates the market and major economies across the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.The Antisense & RNAi Therapeutics Global Market Report 2021 covers antisense & RNAi therapeutics market drivers, antisense & RNAi therapeutics market trends, antisense & RNAi therapeutics market growth rate, antisense & RNAi therapeutics market major players, player-adopted strategies in the market, and antisense & RNAi therapeutics market size.The global antisense & RNAi therapeutics market is expected to grow from $1.11 billion in 2020 to $1.2 billion in 2021 at a compound annual growth rate (CAGR) of 8.1%.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.
